Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...

LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative ...

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

After hours: February 14 at 7:45:30 PM EST Loading Chart for SLRN ...

Biopharma deal activity in the first month of the year saw the largest January raise thus far, with $28.63 billion in collective funds. While down slightly month over month, the value was comparable ...